Sağlık Öğrencilerinde Teknoloji Bağımlılığı, Benlik Saygısı ve Savunma Mekanizmaları Arasındaki İlişki

Amaç: Bu çalışma hemşirelik öğrencilerinde teknoloji bağımlılığı, savunma mekanizmaları ve benlik saygısı arasındaki ilişkiyi belirlenmek amacı ile yapılmıştır. Yöntem: Mart-Nisan 2021 tarihlerinde Ağrı İbrahim Çeçen Üniversitesi Sağlık Yüksekokulu Hemşirelik Bölümü’nde yapılan tanımlayıcı tipteki araştırmada evrendeki tüm (328) öğrencilere ulaşılmaya çalışılarak 296 öğrenci ile yapılmıştır. Verilerin toplanmasında Sosyodemografik Bilgi Formu, Savunma Biçimleri Testi, Teknoloji Bağımlılığı Ölçeği ve Benlik Saygısı Ölçeği kullanılmıştır. Verilerin analizinde, tanımlayıcı istatistikler, bağımsız gruplar t testi, tek yönlü varyans, pearson korelasyon analizi kullanılmış ve istatistiksel anlamlılık için p lt;0.05 sınır değeri kabul edilmiştir. Bulgular: Bu çalışmayan katılan öğrencilerde teknoloji bağımlılığının alt boyutu olan sosyal ağ bağımlılığının daha yüksek olduğu, öğrencilerin telefon kullanım süreleri arttıkça daha fazla teknoloji bağımlısı olduğu ve ilkel savunmaları kullandığı, erkeklerin daha fazla teknoloji ve çevrimiçi oyun bağımlısı olduğu belirlenmiştir. Öğrencilerin teknoloji bağımlılığının düşük düzeyde olduğu, benlik saygısının ve olgun savunmaları kullanımlarının ise orta düzeyde olduğu belirlenmiştir. Sonuç: Araştırmaya katılan öğrencilerin ilkel savunmalar ile teknoloji bağımlılığı, sosyal ağ bağımlılığı arasında ve benlik saygısı ile ilkel savunmalar, teknoloji ve sosyal ağ bağımlılığı arasında pozitif yönde anlamlı ilişkiler olduğu tespit edilmiştir

Cerrahi Girişim Geçiren Hastaların Sağlık Bilgisine Ulaşmada İnternet Kullanımı ve E-Sağlık Okuryazarlığının Belirlenmesi

Amaç: Araştırma cerrahi girişim geçiren hastalarda sağlık bilgisine ulaşmada internet kullanımı ve E-Sağlık okuryazarlığını belirlemek amacıyla yapıldı. Yöntem: Tanımlayıcı ve kesitsel türdeki bu araştırmaya Türkiye’nin doğu bölgesindeki bir devlet hastanesinin cerrahi kliniklerinde cerrahi girişim geçiren gönüllü 360 hasta dahil edildi. Verilerin toplanmasında hastalara yönelik sosyodemografik bilgi formu, internet kullanımına ilişkin anket ve E-Sağlık Okuryazarlığı Ölçeği kullanıldı. Araştırma öncesinde etik kurul izni alındı. Bulgular: Araştırmada hastaların çoğunluğunun tanı hakkında bilgi için internet kullandığı, internetten edindikleri bilgilerin sağlıkla ilgili karar ve uygulamalarını etkilediği, konu ile ilgili olarak çok fazla sonuca ulaşıldığında aralarında seçim yapmakta zorlandıkları ve internette bilgi kirliliği olduğunu düşündükleri saptanmıştır. Hastaların ‘E-Sağlık Okuryazarlık’ ölçeği puan ortalaması orta düzeydedir. ‘E-Sağlık Okuryazarlık’ düzeyi ile yaş arasında negatif yönde bir ilişki tespit edilmiştir (p gt;0.05). Araştırmada eğitim ve gelir seviyesi daha iyi olan, hastalık hakkında daha fazla bilgi sahibi olan ve sağlık sorunu için internet araştırması yapan hastaların E-Sağlık Okuryazarlık seviyeleri daha yüksektir.Sonuç: Hastaların E-Sağlık okuryazarlık düzeyleri orta seviyedir. Hastalara, E-Sağlık Okuryazarlık düzeyini arttırmaya yönelik eğitimler verilmesi ve uzmanlar tarafından E-sağlık bilgi kaynaklarına ilişkin güvenilir, kolay ulaşılabilen inovatif süreçlerin oluşturulması önerilmektedir

The prevalence of pandemic anxiety, anxiety and depression during the covid-19 pandemic in Turkey

Background: This prevalence study involved participants from various cities in Turkey was conducted in April 2020, during the coronavirus pandemic in Turkey, with a view to evaluate the pandemic-related anxiety, generalized anxiety, and depression in the society. Method: The study was conducted with 1267 people in more than 70 cities in Turkey. The study data were obtained by means of online data collection forms, due to the risks posed by the contagious COVID-19 disease in face to face interviews. The Demographic Properties Form, the Utkan Pandemic Anxiety (UPA) scale, the Generalized Anxiety Disorder (GAD-7) scale, and the Beck Depression Inventory for Primary Care (BDI-PC) were utilized as data collection tools. Results: The average value for the UPA scale for the sample was calculated as 10.5 +/- 0.257 points, for the GAD-7 scale as 5.5 +/- 0.153 points, and for the BDI-PC as 3.8 +/- 0.095 points. The cut-off threshold for the UPA scale was exceeded by 34%, for the GAD-7 scale by 25.7%, and for the BDI-PC by 30.9% of the sample. Conclusion: It was concluded that the level of pandemic-related anxiety in the community was high, that the level of generalized anxiety and depression had increased in comparison to pre-pandemic times, and that women had a higher risk of pandemic-related anxiety, generalized anxiety, and depression, because they were a group at risk, and also due to the effect of media surveillance and reports

Investigating the Factors Affecting Depression By Using Structural Equation Modeling

The objective of the research was to study the factors affecting depression in general population. Materials and Methods. A total of 1,291 individuals at the age of 15-68 years participated in this cross-sectional study. The Demographic Information Form, the Beck Depression Inventory for Primary Care and the Generalized Anxiety Disorder Scale were used as data collection tools. The data obtained were evaluated in the SPSS 23 package program. Missing data were validated for extreme values, and, then, tested for normality and homogeneity. Testing for the research model was implemented by structural equation modeling using the AMOS program. Results. The following goodness-of-fit values were determined for the revised model predicting the factors influencing depression: χ2 = 535.62, χ2/df = 4.74, the normed fit index = 0.95, the Tucker-Lewis index = 0.95, the comparative fit index = 0.96, the goodness-of-fit index = 0.95, the adjusted goodness-of-fit index = 0.94, the root-mean-square error of approximation = 0.05, the root mean square residual = 0.12, which were within acceptable limits. According to our model, the generalized anxiety disorder-7 (t = 15.923; p < 0.001), gender (t = -5.866; p < 0.001), age (t = -8.193; p < 0.001) and marital status (t = -6.107; p < 0.001) had a significant effect on depression. However, there was no significant relationship between depression score and educational status, place of residence, family type, and smoking. Conclusions. In this model of our study, generalized anxiety disorder was found to have the greatest effect on depression, followed by age, marital status, and gender, respectively

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET